PURPOSE: To determine whether androgen blockade produces metabolic changes in urine and increases the risk of calculi after 1 year of treatment. MATERIALS AND METHODS: The study included 38 patients, from the period April 2015 to June 2016, diagnosed with locally advanced prostate cancer or lymph node metastasis, and with an indication of androgen blockade. Androgen blockade was started with luteinising hormone-releasing hormone (LHRH) analogues, and a blood specimen, a fasting urine and 24-h urine were collected at the time of inclusion, and then at 1 year of follow-up. A study was performed at baseline and at 1 year with imaging tests. An analysis of the variables was performed with a p ≤ 0.05 considered as statistically significant. RESULTS: The mean age of the patients included in the study was 72.26 ± 6.75 years. As regards the biochemistry parameters, an increase in osteocalcin (from 16.28 ± 9.48 to 25.56 ± 12.09 ng/ml; p = 0.001) and an increase in β-crosslaps (from 0.419 ± 0.177 to 0.743 ± 0.268 ng/ml; p = 0.0001) were observed. In the urinary parameters, a significant increase was observed in the fasting calcium/creatinine ratio (from 0.08 ± 0.06 to 0.13 ± 0.06; p = 0.002) and in the 24-h calcium renal excretion (from 117.69 ± 66.92 to 169.42 ± 107.18 mg; p = 0.0001). Calculi formation was observed in 12 of the 38 patients included (31.6%), with a mean size of 3.33 ± 1.31 mm. CONCLUSION: Treatment with LHRH analogues, as well as increasing the appearance of metabolic syndrome and speeding up the loss bone mineral density, causes an increase in fasting urine calcium.
PURPOSE: To determine whether androgen blockade produces metabolic changes in urine and increases the risk of calculi after 1 year of treatment. MATERIALS AND METHODS: The study included 38 patients, from the period April 2015 to June 2016, diagnosed with locally advanced prostate cancer or lymph node metastasis, and with an indication of androgen blockade. Androgen blockade was started with luteinising hormone-releasing hormone (LHRH) analogues, and a blood specimen, a fasting urine and 24-h urine were collected at the time of inclusion, and then at 1 year of follow-up. A study was performed at baseline and at 1 year with imaging tests. An analysis of the variables was performed with a p ≤ 0.05 considered as statistically significant. RESULTS: The mean age of the patients included in the study was 72.26 ± 6.75 years. As regards the biochemistry parameters, an increase in osteocalcin (from 16.28 ± 9.48 to 25.56 ± 12.09 ng/ml; p = 0.001) and an increase in β-crosslaps (from 0.419 ± 0.177 to 0.743 ± 0.268 ng/ml; p = 0.0001) were observed. In the urinary parameters, a significant increase was observed in the fasting calcium/creatinine ratio (from 0.08 ± 0.06 to 0.13 ± 0.06; p = 0.002) and in the 24-h calcium renal excretion (from 117.69 ± 66.92 to 169.42 ± 107.18 mg; p = 0.0001). Calculi formation was observed in 12 of the 38 patients included (31.6%), with a mean size of 3.33 ± 1.31 mm. CONCLUSION: Treatment with LHRH analogues, as well as increasing the appearance of metabolic syndrome and speeding up the loss bone mineral density, causes an increase in fasting urine calcium.
Entities:
Keywords:
Analogues LHRH; Bone; Kidney stones; Lithogenic markers; Prostate cancer
Authors: Miguel A Arrabal-Polo; María del Carmen Cano-García; Benjamin K Canales; Miguel Arrabal-Martín Journal: Curr Opin Urol Date: 2014-11 Impact factor: 2.309
Authors: Dawn L Hershman; Joseph M Unger; Jason D Wright; Scott Ramsey; Cathee Till; Catherine M Tangen; William E Barlow; Charles Blanke; Ian M Thompson; Maha Hussain Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: Enrique Javier Díaz Convalía; María Del Carmen Cano-García; José Luis Miján-Ortiz; Miguel Arrabal-Martín; Miguel Ángel Arrabal-Polo; José Manuel Cózar-Olmo Journal: Med Clin (Barc) Date: 2017-02-27 Impact factor: 1.725
Authors: Handoo Rhee; Jennifer H Gunter; Peter Heathcote; Ken Ho; Phillip Stricker; Niall M Corcoran; Colleen C Nelson Journal: BJU Int Date: 2015-04 Impact factor: 5.588
Authors: Giuseppe Morgia; Giorgio Ivan Russo; Andrea Tubaro; Roberto Bortolus; Donato Randone; Pietro Gabriele; Fabio Trippa; Filiberto Zattoni; Massimo Porena; Vincenzo Mirone; Sergio Serni; Alberto Del Nero; Giancarlo Lay; Umberto Ricardi; Francesco Rocco; Carlo Terrone; Arcangelo Pagliarulo; Giuseppe Ludovico; Giuseppe Vespasiani; Maurizio Brausi; Claudio Simeone; Giovanni Novella; Giorgio Carmignani; Rosario Leonardi; Paola Pinnarò; Ugo De Paula; Renzo Corvò; Raffaele Tenaglia; Salvatore Siracusano; Giovanna Mantini; Paolo Gontero; Gianfranco Savoca; Vincenzo Ficarra Journal: BJU Int Date: 2015-09-23 Impact factor: 5.588
Authors: J L Kiwata; T B Dorff; E T Schroeder; M E Gross; C M Dieli-Conwright Journal: Prostate Cancer Prostatic Dis Date: 2016-06-28 Impact factor: 5.554